Kevin Vitting, MD
Nephrology · Wayne, NJNPI 1598762148
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.5% of the total across 104 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 19 manufacturers, the largest accounting for just 15.8% — the pattern of someone who eats at a lot of different presentations.
Across 104 payments — averaging $16.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Vifor Pharma, Inc.$263
- Otsuka America Pharmaceutical, Inc.$229
- Novartis$182
- Mallinckrodt Enterprises LLC$130
- Amgen$116
- Akebia Therapeutics Inc$113
- plus $631 from 13 others
Across 2 payments — averaging $36,098 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$72K
What the payments were for
- Food & beverage$1,58995%
- Education$755%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Vifor Pharma, Inc. | 19 | $263 |
| Otsuka America Pharmaceutical, Inc. | 16 | $229 |
| Novartis | 10 | $182 |
| Mallinckrodt Enterprises LLC | 5 | $130 |
| Amgen | 8 | $116 |
| Akebia Therapeutics Inc | 6 | $113 |
| Travere Therapeutics, Inc. | 7 | $112 |
| Mallinckrodt Hospital Products Inc. | 6 | $95 |
| Bayer | 4 | $68 |
| AstraZeneca | 4 | $57 |
| OPKO Pharmaceuticals, LLC | 4 | $55 |
| Daiichi Sankyo Inc. | 3 | $42 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $33 |
| Lilly USA, LLC | 2 | $33 |
| Ardelyx, Inc. | 2 | $32 |
| GSK | 2 | $32 |
| Fresenius USA Marketing, Inc. | 2 | $27 |
| Scpharmaceuticals Inc. | 1 | $23 |
| ANI Pharmaceuticals, Inc. | 1 | $21 |
How this compares
$1,664 in reported general payments places this provider in the 60th percentile of 413 nephrology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 105 | $92,178 |
| FarxigaDapagliflozin Propanediol | 78 | $62,814 |
| VelphoroSucroferric Oxyhydroxide | 11 | $26,895 |
| LokelmaSodium Zirconium Cyclosilicate | 19 | $23,505 |
| Cinacalcet Hcl | 64 | $23,347 |
| ProcritEpoetin Alfa | 19 | $20,490 |
| EliquisApixaban | 15 | $18,964 |
| AranespDarbepoetin Alfa In Polysorbat | 17 | $15,932 |
| Sevelamer Carbonate | 66 | $14,694 |
| Sodium Polystyrene Sulfonate | 94 | $7,773 |
| Valsartan | 99 | $3,487 |
| Potassium Citrate ErPotassium Citrate | 27 | $2,821 |
| Midodrine Hcl | 26 | $1,615 |
| Furosemide | 188 | $1,425 |
| Metoprolol Succinate | 95 | $1,348 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $57 | $86,31997 claims |
| Fresenius USA Marketing, Inc.Velphoro | $27 | $26,89511 claims |
| AmgenAranesp | $116 | $15,93217 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $21 | $3,48799 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 413 nephrology providers in New Jersey.
Other nephrology in Wayne
- Sanjay ShahWayne$6K
- Lawrence ByrdLivingston$338K
- Jeffrey FeldmanUnion$315K
- Joshua KaplanNewark$154K
- Vadim FinkielsteinPrinceton Junction$139K
- Neeraj SinghNew Brunswick$133K
- Harry DounisNeptune$75K
- Kenneth LissEatontown$75K
- Jeffrey GoodmanFlorham Park$70K
- Arif AsifNeptune$42K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.